Maraviroc plus atazanavir/ritonavir in a nuke-sparing regimen in treatment-naive patients
1 August 2012. Related: Conference reports, Antiretrovirals.
Antiretrovirals
Five-year results from raltegravir registrational studies
1 August 2012. Related: Conference reports, Antiretrovirals.
First report: atazanavir-related gallstones (cholelithiasis)
1 August 2012. Related: Conference reports, Antiretrovirals, Side effects.
Novel lopinavir/ritonavir sprinkle formulation for children in resource-limited settings
1 August 2012. Related: Conference reports, Antiretrovirals, Paediatric care.
Update on new antiretrovirals for children and adolescents
1 August 2012. Related: Conference reports, Antiretrovirals, Paediatric care.
Efavirenz levels variable in children in the CHAPAS-3 study
1 August 2012. Related: Conference reports, Antiretrovirals, Paediatric care.
Early initiation of ART is associated with growth recovery in children in NEVEREST-2
1 August 2012. Related: Conference reports, Antiretrovirals, Paediatric care.
Lipid profile in children in PREDICT: immediate versus deferred nevirapine-based ART
1 August 2012. Related: Conference reports, Antiretrovirals, Paediatric care.
Skeletal muscle toxicity and raltegravir
1 August 2012. Related: Conference reports, Antiretrovirals, Side effects.
Dolutegravir indicates superiority compared to efavirenz in treatment-naïve patients: top-line results only
1 August 2012. Related: Antiretrovirals.
FDA update to darunavir label: severe skin reactions
1 August 2012. Related: Antiretrovirals.
Outcomes from switches to atazanavir/r in London
1 June 2012. Related: Conference reports, Antiretrovirals, Side effects.
Studies on pipeline ARVs
1 June 2012. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Fosamprenavir paediatric dosing approved in US for ages 4 weeks to <6 years
1 June 2012. Related: Antiretrovirals.
FDA advisory panel vote 13:1 for approval of Quad
1 June 2012. Related: Antiretrovirals.
FDA advisory hearing supports approval of tenofovir/FTC for PrEP
1 June 2012. Related: Antiretrovirals.
Pharmacokinetics of atazanavir/ritonavir plus raltegravir
1 June 2012. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Renal impairment in the D:A:D study
1 June 2012. Related: Conference reports, Antiretrovirals, Coinfections and complications.
Early data for rilpivirine long acting formulation supports further investigation for PrEP
1 June 2012. Related: Conference reports, Antiretrovirals, HIV prevention and transmission.
Darunavir use during pregnancy
1 June 2012. Related: Conference reports, Antiretrovirals, Women's health, Pregnancy, PK and drug interactions.
Quad fixed-dose integrase combination: phase 3 studies at week 48
1 April 2012. Related: Conference reports, Antiretrovirals.
Dolutegravir studies continue to show promise
1 April 2012. Related: Conference reports, Antiretrovirals, Pregnancy.
Tenofovir prodrug: 10 day monotherapy study sets dose at 25 mg for easier coformulation
1 April 2012. Related: Conference reports, Antiretrovirals.
Paediatric formulations of ARVs: including an exciting new class
1 April 2012. Related: Conference reports, Antiretrovirals, Paediatric care.
High prevalence of d4T-associated lipodystrophy including lipoatrophy in children
1 April 2012. Related: Conference reports, Antiretrovirals, Paediatric care.
Dolutegravir Expanded Access Programme
1 April 2012. Related: Antiretrovirals.
FDA approves etravirine for treatment-experienced children 6 to 18 years of age and new scored 25 mg tablet for paediatric dosing
1 April 2012. Related: Antiretrovirals, Paediatric care.
Similar efficacy and a few gender related differences in side effects with rilpivirine vs efavirenz at 96-weeks
1 February 2012. Related: Conference reports, Antiretrovirals, Pregnancy.
The effect of BMI on efficacy, safety and tolerability of lopinavir/r in women
1 February 2012. Related: Conference reports, Antiretrovirals, Women's health.
Poorer adherence and loss to follow up in Kenyan women who are pregnant when enrolled to ART programmes
1 February 2012. Related: Conference reports, Antiretrovirals, Pregnancy.
Nevirapine prolonged release (PR) once-daily formulation available in the UK
1 February 2012. Related: Antiretrovirals.
Etravirine 200 mg formulation available in UK
1 February 2012. Related: Antiretrovirals.
Tenofovir label extended to paediatric indication
1 February 2012. Related: Antiretrovirals.
FDA approve US paediatric dose for raltegravir
1 February 2012. Related: Antiretrovirals.
FDA approve paediatric dose for darunavir
1 February 2012. Related: Antiretrovirals.
Efavirenz dose increase to 800 mg QD with rifampin in patients >50 kg
1 February 2012. Related: Antiretrovirals.
Raltegravir achieves superiority over efavirenz after four years
1 December 2011. Related: Conference reports, Antiretrovirals.
Statin blocks negative impact of PIs on bone formation in vitro
1 December 2011. Related: Conference reports, Antiretrovirals.
Intracellular raltegravir concentrations better with twice-daily than once-daily dosing
1 December 2011. Related: Conference reports, Antiretrovirals.
Rilpivirine (Edurant) and rilpivirine/FTC/tenofovir FDC (Eviplera) approved in Europe
1 December 2011. Related: Antiretrovirals.
FDA updates US label for darunavir for serious rash
1 December 2011. Related: Antiretrovirals.
FDA updates US label for raltegravir due to serious rash
1 December 2011. Related: Antiretrovirals.
Lopinavir concentrations suboptimal at reduced dose of lopinavir/ritonavir 200/50 mg twice daily
1 December 2011. Related: Antiretrovirals, PK and drug interactions.
Switching to 50mg ritonavir dose for selected protease inhibitors
1 December 2011. Related: Antiretrovirals, PK and drug interactions.
New formulations, acquisitions and company announcements
1 December 2011. Related: Antiretrovirals.
US guidelines (DHHS) update recommendations for first-line combinations (October 2011)
1 December 2011. Related: Antiretrovirals.
Once-daily nevirapine approved in Europe
1 October 2011. Related: Antiretrovirals.
Fixed-dose combination of rilpivirine/tenofovir/FTC (Eviplera) recommended for approval in Europe
1 October 2011. Related: Antiretrovirals.
ViiV withdraw European application for once-daily maraviroc
1 October 2011. Related: Antiretrovirals.
Treatment is prevention: ARV treatment in HPTN-052 reduces transmission by at least 96%: single transmission in treatment arm occurred before viral suppression
1 August 2011. Related: Conference reports, Antiretrovirals, HIV prevention and transmission.
Daily oral tenofovir/FTC PrEP reduces heterosexual transmission by 63% in the TDF2 study
1 August 2011. Related: Conference reports, Antiretrovirals, HIV prevention and transmission.
Tenofovir/FTC vs tenofovir as daily oral PrEP: preliminary results from Partners PrEP
1 August 2011. Related: Conference reports, Antiretrovirals, HIV prevention and transmission.
Elvitegravir vs raltegravir: 48 week results in treatment-experienced patients
1 August 2011. Related: Conference reports, Antiretrovirals.
Dolutegravir: 48 week results from phase II study in treatment-naive patients
1 August 2011. Related: Conference reports, Antiretrovirals.
Lersivirine: 48 week results compared to efavirenz in phase 2 treatment-naive study
1 August 2011. Related: Conference reports, Antiretrovirals.
Maraviroc plus atazanavir/r without nukes versus standard of care: 48 week results
1 August 2011. Related: Conference reports, Antiretrovirals.
SPARTAC trial: treatment in primary infection for 48 weeks shows small delay in disease progression
1 August 2011. Related: Conference reports, Antiretrovirals.
Paediatric antiretroviral pipeline: darunavir and raltegravir
1 August 2011. Related: Conference reports, Antiretrovirals, Paediatric care.
FDA approve new NNRTI rilpivirine (Edurant) in the US
1 August 2011. Related: Antiretrovirals.
FDA approve new NNRTI-based fixed dose combination of rilpivirine/tenofovir/FTC (Complera) in the US
1 August 2011. Related: Antiretrovirals.
The antiretroviral pipeline
14 July 2011. Related: Pipeline report, Antiretrovirals.
Atazanavir in pregnancy: 155 cases in London clinics
1 May 2011. Related: Conference reports, Antiretrovirals, Women's health, Pregnancy.
Quad reduces levels of oral contraceptives
1 May 2011. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Elvitegravir/cobicistat and acid reducing agents
1 May 2011. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Lopinavir/r reduces levels of rifabutin
1 May 2011. Related: Conference reports, Antiretrovirals, PK and drug interactions.